Identification of Jaundice in Newborns Using Smartphones

Overview

Neonatal jaundice is a common and most often harmless condition. However, when unrecognized it can be fatal or cause serious brain injury. Three quarters of these deaths are estimated to occur in the poorest regions of the world. The treatment of jaundice, phototherapy, is in most cases easy, low-cost and harmless. The crucial point in reducing the burden of disease is therefore to identify then children at risk. This results in the need for low-cost, reliable and easy-to-use diagnostic tools that can identify newborns with jaundice.

Based on previous research on the bio-optics of jaundiced newborn skin, a prototype of a smartphone application was developed and tested in a pilot study and the application refined.

This smartphone application will now be evaluated in a clinical trial set in two hospitals in Norway. The smartphone application gives immediate estimates of bilirubin values in newborns, and these estimates will be compared to the bilirubin levels measured in standard blood samples, as well as the results from ordinary transcutaneous measurement devices.

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 15, 2021

Detailed Description

The smartphone jaundice app system works by taking pictures of newborns with a custom-made color calibration card placed on their chest. This makes it possible to measure the skin color precisely regardless of the specific light source that is used to illuminate the newborn. The measured skin color is then compared with items in a database of simulated newborn skin colors. These simulated newborn skin colors have been created using numerical simulations of how light moves through skin, with varying skin parameters including, but not limited to, skin thickness, blood concentration, melanin, and of course bilirubin, the pigment that causes jaundice. By comparing the measured skin color with the simulated skin colors that are most similar to it, the investigators can then estimate the bilirubin concentration in the newborn's skin by e.g. averaging the bilirubin concentrations used to create these simulated skin colors.

In a group of 200 newborns with varying degree of jaundice, correlation between smartphone bilirubin estimates will be compared with total serum bilirubin and standard transcutaneous bilirubinometry.

Interventions

  • Device: Bilirubin estimates from Smartphone Application
    • Bilirubin estimates through color analysis of digital images obtained through smartphone application.
  • Diagnostic Test: Bilirubin concentration measured in standard blood samples
    • Bilirubin measured in total serum bilirubin.
  • Device: Bilirubin estimates from standard transcutaneous device
    • Bilirubin estimates performed by transcutaneous device ( Dräger JM-105)
  • Other: Visual assessment of jaundice
    • Degree of jaundice will be assessed by Kramer scale

Arms, Groups and Cohorts

  • Experimental: Newborns in St.Olavs Hospital and Haugesund Hospital
    • All newborns will be examined through 4 different methods of determining jaundice.

Clinical Trial Outcome Measures

Primary Measures

  • Smartphone application sensitivity
    • Time Frame: 5 minutes
    • Sensitivity of the smartphone application to detect severe jaundice, defined as total serum bilirubin value > 250 umol/l.

Secondary Measures

  • Repeatability
    • Time Frame: 5 min
    • To evaluate the repeatability of multiple measurements with the new smartphone tool
  • Correlation between bilirubin estimates by smartphone pictures and by total serum bilirubin
    • Time Frame: 5 minutes
    • Estimate of bilirubin levels from smartphone pictures, compared with bilirubin measurements in total serum. Correlation will be expressed by Pearson correlation coefficient, r.
  • Correlation between bilirubin estimates by smartphone pictures and by standard transcutaneous readings.
    • Time Frame: 5 minutes
    • To evaluate the correlation between bilirubin estimates from a smartphone application and bilirubin estimates from a standard transcutaneous device in newborns with varying degree of jaundice. Correlation will be expressed by Pearson correlation coefficient, r.
  • Correlation between bilirubin estimates by smartphone pictures and visual assessment of jaundice
    • Time Frame: 5 min
    • - To evaluate the correlation between bilirubin estimates from a smartphone application and bilirubin estimates from visual inspection in newborns with varying degree of jaundice

Participating in This Clinical Trial

Inclusion Criteria

  • Born in St.Olavs hospital, Trondheim or in Haugesund Hospital, Norway
  • Born with gestational age >36+6
  • Birth weight ≥ 2500g and <4500g
  • Age 1 – <15 days
  • Are having a blood sample performed, as newborn screening or for jaundice assessment

Exclusion Criteria

Infants needing intensive treatment. This includes:

  • Infants in the need for respiratory support
  • Infants with conditions that could compromise skin circulation, as sepsis, heart failure or other
  • Infants that have received phototherapy

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 14 Days

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • St. Olavs Hospital
  • Collaborator
    • Norwegian University of Science and Technology
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Siri Forsmo, md prof, Study Director, Norwegian University of Science and Technology
  • Overall Contact(s)
    • Anders Aune, 0047 95034601, a.aune@ntnu.no

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.